The New England journal of medicine 2006-02-09
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Abstract
Background
We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck.
Methods
Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-dose radiotherapy alone (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface area, followed by 250 mg per square meter weekly for the duration of radiotherapy. The primary end point was the duration of control of locoregional disease; secondary end points were overall survival, progression-free survival, the response rate, and safety.
Results
The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 months among those given radiotherapy alone (hazard ratio for locoregional progression or death, 0.68; P=0.005). With a median follow-up of 54.0 months, the median duration of overall survival was 49.0 months among patients treated with combined therapy and 29.3 months among those treated with radiotherapy alone (hazard ratio for death, 0.74; P=0.03). Radiotherapy plus cetuximab significantly prolonged progression-free survival (hazard ratio for disease progression or death, 0.70; P=0.006). With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.
Conclusions
Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)
Related Questions
How are you managing patients with H&N cancers meriting definitive concurrent chemoRT during cisplatin shortages?
If cisplatin cannot be used, other systemic therapies should be considered. The NCCN guidelines list various regimens, as noted below. Given the improvements in the delivery and quality of radiation therapy, I am a believer that single agent carboplatin (AUC 6 Q 3 weeks or AUC 2 Q weekly) can be sub...
Do you give Cetuximab concurrently with SBRT for recurrent head and neck cancers previous treated with definitive radiation?
This is an area of active clinical trial development esp. as it relates to immunotherapy concurrent with SBRT. That being said, we certainly have phase I, II, and preliminary phase III data suggesting that SBRT in the setting of recurrent disease is safe and may offer extended LR control rates in a ...
What is your approach in deciding on definitive therapy for locally advanced, HPV-negative head and neck cancer unsuitable for standard cisplatin based chemo?
The real answer is it depends on the medical oncologist as (s)he typically administers the therapy.It also depends on why cisplatin is contraindicated. Is it an otherwise healthy patient who has renal or hearing issues, or is it an elderly patient with a marginal PS for whom cytotoxics, in general, ...
What approach do you take to determine dose constraints for conventionally fractionated reirradiation of the head and neck?
Great question, very challenging scenario.In general, try to minimize the margins for re-RT, and use IGRT, especially if you are close to the neurologic critical structures. (Optics, brainstem, spinal cord, plexus, temporal lobe.)Specific doses and whether you exceed limits: that really depends on w...
Do you recommend altered fractionation when using cetuximab with head and neck RT?
The 5-year update of the randomized study of RT vs RT and cetuximab for HN cancer added additional factors related to better outcome in patients receiving cetuximab (in addition to the findings that only oropharyngeal cancer benefited, published previously in the NEJM paper). The additional factors ...